While preparing information for Japanese collaborators, I opened the NHIA’s catastrophic-illness page. Its table lists conditions, diagnostic codes, and certificate validity periods. For someone who needs to renew a certificate, those entries mean more than a classification.
A relative of mine entered the catastrophic-illness system because of cancer and renewed the certificate every three years. Follow-up visits, waiting for results, preparing another application: I have seen and lived that rhythm. But my relative’s three-year period cannot stand for every cancer.
When a catastrophic-illness certificate expires, does NHI stop covering treatment? To answer that, first separate certificate validity, co-payment exemption, and coverage of medical services.
Separate certificate validity, co-payment exemption, and medical coverage
These matters are connected, but they answer different questions.
| What to establish | The question it answers |
|---|---|
| Catastrophic-illness certification and its validity | Has this status been approved, and when is a new application needed? |
| Scope of co-payment exemption | Does this visit fall within the rules exempting the patient from co-payments? |
| Coverage of a medical service or drug | Does this test, treatment, or medicine meet NHI’s coverage rules and conditions? |
The NHIA’s English explanation makes the central point directly: during the certificate’s validity period, care for the catastrophic illness or related conditions is exempt from outpatient or inpatient co-payments. A separate visit solely for an unrelated condition generally follows ordinary rules. However, other treatment provided by the same physician during a catastrophic-illness outpatient visit, and concurrent care during hospitalization, still require checking the exemption scope under Article 6 of the co-payment exemption regulations. Different diagnostic names alone do not settle the question.
A certificate therefore does not mean every medical expense is waived. Nor does it automatically make every new therapy or drug eligible for reimbursement. The status and expense scope addressed by the certificate cannot replace the coverage rules for a particular medical service.
Cancer certificates are not uniformly valid for three years
My earlier title contrasted permanent certification for rare diseases with three years for cancer. That was an oversimplification.
As checked on November 3, 2026, the validity table listed on the NHIA’s catastrophic-illness page was revised on September 16, 2024, and applies from January 1, 2025. The first category in the annex concerns cancers requiring active or long-term treatment, then distinguishes subcategories.
| Subcategory listed in the annex | Certificate validity |
|---|---|
| Malignant neoplasm of the thyroid gland | Three years |
| Stage I malignant neoplasms of the oral cavity, oropharynx, or hypopharynx; stage I breast cancer; stage I cervical cancer | Three years |
| Other malignant neoplasms outside those subcategories, still subject to the category’s requirements | Five years |
Three years is not a common validity period for all cancers. Nor should every three-year entry be described as an “early cancer with a high cure rate.” Read the condition, stage, and requirements together.
Determining an individual’s applicable status still requires a diagnosis, supporting information, and NHIA approval. A cancer’s name, or someone else’s renewal experience, is not enough to determine your own certificate period.
The validity table is not a ranking of disease severity
The table should not be reorganized into five official grades called permanent, five years, three years, one year, and individual assessment, with one explanation of disease progression assigned to each.
For example, category 30 of the annex gives permanent validity to rare diseases designated and announced by the central competent authority under the law. “Rare disease” here has a legal scope. An illness being uncommon in everyday language does not establish eligibility.
For chronic renal failure meeting the relevant conditions, the same table distinguishes whether regular dialysis is already known to be necessary at application: permanent validity if confirmed, three months if not yet confirmed. That is a rule for specific circumstances, not a long-to-short ranking based solely on a disease name.
Acute cerebrovascular disease is handled differently again: within one month after acute onset, a physician can make the determination directly, without a certificate application. This is not a matter of first receiving a certificate valid for one month. A search interface should distinguish it from ordinary certificate validity.
Permanent validity also remains subject to legal conditions. Article 5 provides for revocation or termination when a certificate is found not to meet the requirements. A safer way to read the table is this: read validity periods together with their conditions, rather than using them to rank diseases or patients.
Renewal checks eligibility; it does not score treatment outcomes
Periodic renewal marks a point at which continued eligibility must be assessed. It does not predict that a patient will necessarily recover after three or five years, or that all treatment ceases to be covered on the expiry date.
In a historical explanation of cancer-certificate renewal, the NHIA distinguished certification from coverage of later tests: not issuing a further certificate does not mean related examinations and tests cease to be covered. That is a historical policy explanation. Individual care still needs to be assessed under current coverage and co-payment rules.
If expiry is approaching, I would first ask the treating hospital about renewal arrangements, then consult the NHIA renewal FAQ and Article 5. Different original validity periods have different reapplication timings. Establishing when to submit and which documents are needed is more useful than memorizing the table.
Cancer renewal also requires more than submitting an old certificate. The NHIA specifies an assessment form and evidence supporting the continuing need for active or long-term treatment. Continued eligibility is subject to the prescribed review; automatic extension cannot be guaranteed.
These steps can be burdensome for families. Explaining them should help people prepare early and distinguish whether their present question concerns treatment, coverage, or certificate renewal.
A diagnostic code helps locate an entry, but does not determine validity by itself
I studied life sciences and previously worked as a medical technologist, so diagnostic coding in medical systems is familiar to me. But in this table, a code is only part of the search.
Article 2 requires more than a diagnostic certificate carrying an international disease-classification code. Applications also need supporting material such as a medical-record summary or examination reports. Certain categories require additional forms. One code cannot replace the full conditions and review process.
I created a four-language lookup tool to make a difficult table easier to search. A website can help locate information; it cannot approve personal eligibility. Translating it into several languages does not give it authority to determine validity periods either.
Versions matter as well. The NHIA page lists the validity table and diagnostic-code mapping updates separately. One date cannot represent every part of the dataset. After locating an entry, return to the official documents to check the condition, subcategory, requirements, and applicable version.
AI can help people search the table, but cannot supply conclusions the system has not established
I remain interested in this dataset’s structure. Conditions, codes, requirements, validity, application procedures, and versions, if well organized, can help people identify where their question belongs.
But I do not have sufficient evidence about the system’s design to call the table a “thirty-year actuarial result.” Different validity periods do not establish it as an early prototype of AI-based tiered reimbursement. Reassessment intervals, allocation of medical resources, and algorithms’ participation in decisions are different levels of inquiry.
If AI is used for lookup, I would want it to do a few concrete things first: link to the original entry, retain conditions, identify versions, and distinguish applications from direct physician determinations. Questions about personal eligibility should return to treating physicians and the NHIA.
That is where I believe the information interface can improve. It should reduce the difficulty of finding an answer, rather than lead readers toward a promise the table never made.
Establish the eligibility rules first, then discuss what the system means.


💬 Comments
Loading...